Drug Profile
Research programme: antithrombotic therapies - NicOx
Alternative Names: Antithrombotic therapies research programme - NicOx; NCX 5022Latest Information Update: 21 Nov 2006
Price :
$50
*
At a glance
- Originator NicOx
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 11 Mar 2003 Preclinical trials in Thrombosis in France (unspecified route)